RetatrutideClinical Trial Data & Pharmacokinetics Based Automated Dosing Calculator

Retatrutide Dosing Math — Unique Among GLP-1s

Retatrutide is sometimes called a GLP-3 agonist for its triple-receptor action. Accurate count; misleading framing — GLP-1 is one of three receptors, and reta doesn't target them equally.

These are potency ratios, not efficacy multipliers. All three receptors fire at native peak once engaged¹² — what differs is the dose required to engage them. GIP binds tightest by far, which is why 1 mg of retatrutide reaches more GIP engagement than tirzepatide does at its 15 mg ceiling¹⁴.

The receptors don't saturate together, and that's the point. GIP fills fast — by 1 mg most of its work is done; past 4 mg it climbs barely at all. GLP-1 grows steadily across the full range. Glucagon starts near zero and grows slowly. Climbing from 1 mg to 12 mg mostly buys more GLP-1 (more satiety, more GI burden) and more glucagon (more heart rate, more peripheral effects, more liver fat-burning) — not more GIP. Microdose retatrutide isn't a weak version of the full dose. It's a different signal mix.

The trial data this article rests on come from non-diabetic obese adults averaging ~109 kg and BMI 37 in Jastreboff 2023 Phase 2,¹ with the lean reference cohort drawn from Coskun 2022 Phase 1 SAD (BMI 26.3 mean, healthy non-diabetic).¹⁶ Headline percentages describe what happened to one population at one exposure — reading them as universal is the most common mistake on this drug.

What you feel at each band

Microdose (0.25–2 mg)

GIP is fully active. Retatrutide binds the GIP receptor ~13× tighter than tirzepatide at physiological albumin (Coskun Table S2: reta GIPR EC50 4.36 nM vs tirz 56.3 nM at 1% HSA), so 1 mg achieves 57% GIP saturation — higher than 15 mg of tirzepatide. Fat cells start running an internal heating cycle (futile calcium cycling⁵), and the pancreas amplifies meal-time insulin response.

The glucagon arm engages tissue by tissue, not all at once. The liver activates first — the 1 mg arm produced 51% liver-fat reduction at 48 weeks in the Phase 2 MASLD substudy⁶. Visceral fat mobilizes early too. The cardiac pacemaker and peripheral nerves stay off at this dose. Insulin sensitivity shifts more than weight loss alone predicts: the 1 mg arm produced −37.5% fasting insulin and −36.3% HOMA2-IR at only −8.7% weight loss⁶.

How microdose performs depends on metabolic state and cardiovascular sensitivity, and these pull in opposite directions. In severe insulin resistance, the signal gets absorbed by the metabolic deficit — 0.5 mg failed to separate from placebo in the Phase 2 T2D trial. In a lean, cardiovascularly responsive body, the same dose produces real heart-rate response: Phase 1 measured +10 bpm 8-day average at 1 mg single dose in healthy lean Asian subjects vs +0.7 bpm at chronic steady state in the obese trial population¹⁶. The translation isn't a single multiplier — see population shift below for the per-endpoint shifts that matter.

What microdose doesn't deliver: aggressive weight loss in the trial cohort (1 mg = −8.7% at 48 wk in Jastreboff), peripheral lipolysis (subcutaneous fat doesn't engage), or the maximum liver-fat reduction.

For a lean reference user (75 kg, BMI 26, normoglycemic) dosed chronically at 1 mg weekly, the projected weight loss at 48 weeks lands in roughly −7% to −13% of body weight. The bracket is wide because reta has no chronic data at this phenotype — Coskun is single-dose only — and the projection is built from reta's measured single-dose body-weight signal at day 43, the accumulation factor at weekly dosing, and the tirzepatide weight-loss-vs-time trajectory from the SURMOUNT-1 BMI <30 stratum (used as math structure, not as a reta substitute). The directional claim — meaningful weight loss happens at sub-trial-cohort doses for lean users, with cardiovascular cost arriving alongside it — is more robust than the magnitude. The math is in the appendix.

Moderate (4–6 mg)

GIP near-saturated (78% engagement at 4 mg). The GLP-1 arm crosses into meaningful satiety — eating becomes work, GI burden rises during titration. The cardiac threshold crosses in the trial population: HR rises +2–4 bpm at 4 mg depending on titration speed. Liver fat-burning accelerates (4 mg = 59% reduction). Phase 2 weight loss at 48 weeks: 4 mg = −17.1%¹.

Heart rate in this band isn't only a side effect. Each 1 bpm of sustained resting HR adds roughly 30–50 kcal/day to BMR from cardiac work alone⁷. At +4 bpm raw — the 4 mg arm's average — that's 120–200 kcal/day, or 5–9 kg of fat-equivalent burn over 48 weeks. The HR rise is part of why higher doses lose more weight; the metabolic cost doesn't subtract cleanly from the efficacy.

High (8–12 mg)

GIP plateaued. GLP-1 carrying the additional weight-loss work as dose climbs. Glucagon at full strength — peak HR (+9.2 bpm at 12 mg, 24-week peak; attenuating to 6 bpm by week 48), peripheral lipolysis active, cutaneous hyperesthesia and burning-and-tingling sensations in hands and feet at 12.9% in the 12 mg arm vs 1.4% on placebo¹³. Phase 2 weight loss at 48 weeks: 8 mg = −22.8%, 12 mg = −24.2%¹. Phase 3 (TRIUMPH-4, 68 weeks): 12 mg = 28.7%⁸.

The 8 mg arm captures 94% of the 12 mg arm's effect (placebo-adjusted: 8 mg = −20.7 pp, 12 mg = −22.1 pp). The 8 → 12 mg step buys little additional weight loss for substantial additional cost. Going past 8 mg only makes sense if the deep-responder tail (≥25% loss in 36% of patients, ≥30% in 19%) is the goal, or if maximum liver-fat reduction is the indication.

This band fits readers with high-BMI obesity, severe MASLD, established cardiovascular risk where SELECT-grade weight loss matters, or specific severe metabolic phenotypes. It doesn't fit lean users or microdose-targeted protocols. AE-related discontinuation at 12 mg ran 18.2% vs 4% on placebo — about one in five users couldn't tolerate the top dose.

A higher dose doesn't just suppress appetite harder — it forces more expenditure. Effective maintenance for most users sits well under the trial maximum.

Population shift — when the trial numbers don't apply to you

The trial population averaged 110 kg and BMI 38. If you're 70 kg and BMI 25 — or South Asian regardless of weight, or cardiovascularly fit at any weight — the same milligrams produce a structurally different exposure and a structurally different physiological response. The shifts don't compose into a single multiplier; each endpoint translates differently.

Drug exposure (PK). A lighter body has less blood to dilute the same dose. A 70 kg user at 1 mg ends up with about the drug concentration a 110 kg trial subject saw at 1.5 mg.⁹ This part scales linearly with body weight.

Cardiovascular sensitivity. This shift is the big one, and it isn't PK-driven. Lean and metabolically preserved users have higher baseline heart-rate variability and more responsive sympathetic regulation. Retatrutide's Phase 1 SAD — conducted in healthy lean Asian subjects — measured pulse-rate change at +7.6 bpm at 0.3 mg single dose, +10.3 bpm at 1 mg, +25.2 bpm at 4.5 mg¹⁶. The obese trial population at chronic steady state saw +0.7 bpm at 1 mg. The drug-attributable cardiovascular response runs roughly 25-50× larger in the lean cohort at matched dose. Body weight is a small fraction of that gap; the rest is autonomic tone, cardiac mass, baseline HRV, and ethnicity-specific cardiometabolic phenotype.

Hepatic response. Lean and obese populations have different rate-limiting steps. In the obese MASLD substudy, abundant baseline liver fat means even 1 mg drives 51% reduction; β-hydroxybutyrate (the marker of active hepatic fat oxidation) rises only modestly because insulin resistance dampens the readout. In healthy lean subjects, β-OHB stays flat at 1 mg and rises sharply at 4.5 mg — but there's no liver fat to deplete in the first place. The same dose produces different signals across populations because they have different biology to act on.

What this means for dosing outside the trial population:

• Lean, cardiovascularly responsive user (BMI 22–28, low resting HR, normal lipids): start at 0.5 mg. Dose bands compress — moderate weight loss at 2–4 mg rather than 4–8 mg, full weight-loss intensity at 6–8 mg rather than 12 mg. The HR-as-cost framing matters more here, not less. A lean user at 1 mg seeing +4 bpm raw carries 120–200 kcal/day of cardiac BMR cost — meaningful for body composition while operating at what looks like a microdose by milligrams.

• Lean South Asian phenotype. Higher chronotropic sensitivity than European-reference lean at matched body weight. The Phase 1 SAD cohort was 98% Asian, conducted in Singapore — those numbers describe this profile directly. Start at 0.25 mg. Up-titrate by 0.25 mg per 4-week step only if early-titration HR is tolerable.

• High-baseline liver fat (MASLD), regardless of body size: 1 mg already produces meaningful hepatic effect. Climbing past 4 mg buys diminishing returns on liver fat (59% at 4 mg, 82% at 8 mg, 86% at 12 mg).

Reta Dosing: Quick Escalation Comes with a Cost

The Phase 2 trial split the 4 mg and 8 mg cohorts into two titration paths: one starting at 2 mg before climbing (slow ladder), one starting at 4 mg (fast jump). Same final maintenance dose, different rate of climb. The fast version reaches more weight loss on the scale, sooner. That's what the headline gets right. It misses two costs that ride along with the speed.

Worse side effects that don't go away

Same final dose, dramatically different cumulative nausea rates. The slow 8 mg ladder produced 17% cumulative nausea over 48 weeks; the fast 8 mg ladder produced 60% — 3.5× at identical final pharmacology. The slow 4 mg ladder produced 18%; the fast 4 mg ladder produced 36%. The 12 mg slow ladder, despite reaching a higher final concentration than 8 mg fast, produced 45% — less than 8 mg fast. Final dose alone doesn't predict the side-effect bill. Rate of climb does¹⁰ — the brainstem's nausea circuit adapts to a steady signal but gets triggered by sudden jumps in receptor engagement; weight-loss effects respond to total exposure over time, so a slow ladder reaches the same final dose with much less side-effect provocation along the way.¹¹

The 8 mg fast arm doesn't adapt. Every other arm in the trial — including 12 mg slow — peaks during titration (15–40% AE prevalence depending on dose), then declines to single-digit by week 36. The 8 mg fast arm sustains 30–35% AE prevalence from week 8 through week 48. Forty weeks of active GI symptoms in roughly a third of the arm. The 4 → 8 mg single-step at week 4 outruns the system's ability to desensitize; it never catches up.

Worse fat:lean-mass ratio

Same drug, same final receptor engagement at maintenance, structurally different body composition outcome by titration speed. Waist circumference change ÷ weight change acts as a quasi-DEXA proxy: above 1.0 means the lost weight is concentrated in belly fat; near or below 1.0 means it's dispersed across water, lean mass, and surface fat.

Within-pair, week 4. Ratios above 1.0 mean preferential belly-fat loss; ratios near or below 1.0 mean dispersed loss across water, lean mass, and surface fat.

The fast 8 mg arm wins on total weight (−5.3% vs −3.8%) and loses half the waist circumference per unit of weight. The slow 4 mg arm shows the opposite shape: less total weight loss, but what comes off is overwhelmingly belly fat.

Slow ramping keeps the user near caloric balance through the early weeks — low GLP-1 signal, normal food intake. Modest glucagon engagement preferentially mobilizes visceral fat, where glucagon-receptor density is highest. Fast ramping forces caloric deficit through sustained nausea, food intake collapses, and the deficit pulls fuel from everywhere: water, lean mass, subcutaneous fat — proportionally less visceral.

The "extra" weight loss in fast-titration arms isn't extra fat. It's water, lean mass, and surface fat — the kinds you generally want to keep. Slow ramping isn't a tolerability concession; it's how the weight that comes off is the weight you actually wanted to lose.

The Heart-Rate Climb Is Doing Real Metabolic Work

Heart rate elevation on retatrutide is usually framed only as a side effect. It's that — and it's also doing real metabolic work that contributes to weight loss. At the trial's 12 mg dose (+9 bpm raw at 24 weeks), the cardiac contribution is roughly 300–450 kcal/day — a meaningful fraction of why higher doses lose more weight.

The 40–50% fade from peak to week 48 isn't receptor desensitization. Animal data confirms the HR effect persists at the receptor level for at least six months at matched exposure. Whole-system compensation drives the human attenuation: weight loss + baroreflex resetting + sympathetic adaptation. Users who don't lose substantial weight see less fade — the cardiac cost stays close to its peak.

Standard titration schedule for high BMI individuals

1 mg is a tolerance step — drug levels stabilize across the first four weeks, weight change is minimal. The 2 → 4 mg build is where food noise quiets and weight loss begins; GI burden peaks here if titration is rushed. By 6 → 8 mg, weight loss accelerates, the heart-rate climb becomes noticeable, and liver fat reduction picks up. Most users settle at 8 mg — 12 mg is for the deep-responder tail (≥30% loss in about 1 in 5).

Titration schedule for lower BMI / metabolically healthier individuals

At 0.5 mg in this group, food noise quiets, hepatic effects begin, and heart rate may climb a few bpm in the first week — therapy from the start, not a tolerance step. The 1 → 2 mg build strengthens satiety with visible weight loss; cardiac response runs above what the trial numbers predict at the same dose. At 4 → 6 mg the full effect is online and the cardiac threshold crosses earlier than in the trial population — track resting heart rate weekly through this band. 6–8 mg is the effective ceiling for most users here.

Two rules apply to both schedules.

Don't skip the 6 mg step on the way to 8 mg. The direct 4 → 8 mg jump is the one path the trial showed the body doesn't adapt to — sustained 30–35% GI symptoms across 48 weeks while every other arm faded to single-digit prevalence by month 9.

Hold at least 4 weeks per step. Retatrutide's half-life is roughly six days; plasma at a new step doesn't stabilize for almost three weeks. A heart-rate or GI response at one dose can show up after you've already moved to the next.

At chronic steady state on a held dose, plasma oscillates only about 22% above the weekly average (peak-to-trough is ~1.7×). The peak-concentration cost shows up in three specific places: the first dose, each titration step, and missed-then-redose. At chronic maintenance — same dose held more than 4 weeks — the peak-vs-average differential is muted; tolerability scales with average exposure rather than the peak oscillation. Math in the appendix.

For microdose maintenance: 0.5 mg → 1 mg → optional 2 mg, four weeks per step. The hold is the strategy, not a stop on the way to something higher.

Side effects, monitoring, and stopping rules

Side effects on retatrutide come from two distinct receptor sources.

GLP-1-class side effects — nausea, vomiting, diarrhea, slowed gastric emptying. Track GLP-1 receptor engagement. Scale with dose, peak during titration, partially adapt over time. Manageable with: slow titration, not skipping titration steps, eating smaller meals, anchoring intake on protein. The 8 → 12 mg step adds substantial GLP-1 engagement (40% → 49%) — most of the additional GI cost at 12 mg comes from this, not from glucagon.

Glucagon-class side effects — heart rate elevation, dysesthesia (burning/tingling in extremities), cold extremities, sustained lipolysis-related effects, T4-to-T3 thyroid conversion suppression with associated fatigue. Track glucagon receptor engagement. Emerge at threshold doses: HR above 4 mg in the trial population (sooner in lean users), dysesthesia above 8 mg. The full glucagon-class spectrum doesn't appear at microdose because the heart's pacemaker, peripheral nerves, and subcutaneous fat haven't been engaged.

Two flags from this class deserve separate handling. Sustained glucagon signaling can suppress active thyroid hormone production — Free T3 drops while TSH stays normal, so the standard thyroid panel misses it¹³. Users developing unexplained fatigue, brain fog, or cold intolerance should have Free T3 measured, not just TSH. And new-onset atrial fibrillation surfaces in real-world use at higher doses, but isn't pre-specified in the Phase 2 MedDRA capture template — meaning the trial AE inventory under-reports it by design. Pre-existing AF or known structural cardiovascular disease is an explicit contraindication. For users at 6 mg and above with smartwatch ECG capability, monitor for irregular rhythm at each escalation.

Baseline panel before starting

A pre-injection panel makes every subsequent dose decision defensible. Without it, a rising heart rate at week 8 can't be distinguished from a drug effect.

• Resting heart rate and rhythm, recorded for a full week at baseline. ECG if any cardiac history.
• Fasting glucose, HbA1c, fasting insulin — the metabolic starting point.
• Lipid panel — Phase 2 obesity data showed 20% LDL reduction and triglyceride drops in line with weight loss.
• Thyroid panel including Free T3 — not just TSH. Personal or family history of medullary thyroid carcinoma or MEN2 is a hard contraindication across the GLP-1 class.
• Liver enzymes, with imaging if MASLD is on the table.

Tracking on therapy

• Resting HR weekly through titration; biweekly at maintenance.
• Smartwatch ECG checks at each escalation when available, especially past 6 mg.
• Weight and waist circumference weekly, same conditions. Waist trend is the cleaner signal for visceral-fat response.
• Quarterly: fasting glucose, HbA1c, fasting insulin, lipid panel, liver enzymes.
• Free T3 if fatigue appears.

Stopping rules during titration

• Resting HR sustained more than +10 bpm above baseline for two consecutive weeks — hold at current dose until it settles.
• Unresolved GI distress from the previous step — extend the current step before increasing further. Do not stack.
• Dysesthesia at 8–12 mg — reducing to 4–6 mg attenuates it; reducing to 1–2 mg essentially eliminates it.
• New-onset irregular rhythm or smartwatch AF flag — hold dose, get a clinical ECG, do not advance until cleared.

The mid-range (4–6 mg) preserves most of the weight-loss effect — ≥17% at 48 weeks — without the full glucagon-class spectrum. Higher is not automatically better.

Stopping & maintenance

Retatrutide produces stronger regain pressure on discontinuation than semaglutide or tirzepatide. There's no published retatrutide withdrawal trial yet — the framework below is built from Phase 2 dose-response data plus published withdrawal trials of semaglutide (STEP-1 extension, STEP-4) and tirzepatide (SURMOUNT-4), with retatrutide-specific extrapolation called out where it occurs.

The four forces of regain

After stopping retatrutide, four mechanisms can pull weight back up. Three are class-shared; one is retatrutide-specific.

1. Appetite-suppression withdrawal. Gastric emptying returns to baseline; satiety signals fade. Drug washes out over ~30 days at the 6-day half-life. Food noise typically returns around week 3.

1. Lean-mass-driven BMR contraction. Any lean mass lost during the deficit lowers daily energy use unless training and protein rebuild it. Sema STEP-1 DXA showed ~62:38 fat:lean; tirz SURMOUNT-1 DXA ~75:25; retatrutide T2D DXA ~63:37 with a provisional non-T2D pointer at ~75–80:20–25 from TRIUMPH-4 conference quotes.

1. Hunger-hormone rebound + set-point defense. After major weight loss, hunger and energy-conservation signals can persist for about 12 months (Sumithran 2011). Plasma ghrelin during retatrutide treatment or withdrawal hasn't been measured — this layer is mechanism-inferred for retatrutide specifically.

1. Glucagon-axis signal loss — retatrutide-specific. Active hepatic fat oxidation, raised resting metabolic rate, chronic cardiac BMR contribution — gone within weeks of the last dose. The metabolic floor retatrutide was raising drops back down. This is what makes stopping retatrutide structurally different from stopping sema or tirz.

The STEP-1 extension showed semaglutide users regaining about two-thirds of lost weight within 52 weeks of stopping. Retatrutide's curve is expected to be steeper given the fourth force. Phase 3 readouts through 2027 will measure it directly.

The taper

There's no known physical withdrawal syndrome — stopping abruptly doesn't make you acutely sick. But cold-turkey discontinuation may set up regain: appetite returns as the drug washes out, lean mass is already reduced, and the glucagon-arm metabolic lift fades with no direct withdrawal data telling us how large that change is.

The purpose of tapering isn't receptor detox; it's behavioral and metabolic. A taper buys 8–12 weeks of lower-but-still-present appetite suppression in which to rebuild lean mass and lock in eating and training patterns that have to hold once the drug is gone.

The 2–4 mg maintenance band isn't trial-validated, but the receptor math supports it. The 8 mg arm captures 94% of the 12 mg arm's effect; the 4 mg arm engages GIP at 78%, GLP-1 at 23%, glucagon at 3.8% — meaningful signaling at all three receptors, sub-cardiac on glucagon. Maintenance logic from SURMOUNT-4 and STEP-4 supports the broader pattern that continued receptor signal lowers regain risk vs stopping.

For retatrutide specifically, 4 mg looks like the floor that preserves the structurally distinctive features (active hepatic FAO, GIP-driven thermogenesis) without the high-dose costs.

Tracking the transition

Weight weekly, same conditions (morning, fasted, post-void). Waist circumference biweekly — visceral-fat trend tells you whether the glucagon-axis effect is holding or regressing. Resting heart rate biweekly; expect a 2–4 bpm drop through the taper as glucagon-driven cardiac stim fades. Strength (big-three lifts) tracked weekly — strength trend is the leading indicator of lean-mass preservation. Hunger on a 1–10 scale checked daily through weeks 3–6. Fasting glucose and lipids at weeks 4 / 12 / 24.

If RHR drops more than 10 bpm or you experience dizziness, fainting, or chest discomfort, see a clinician — that's outside the expected pattern.

Support during the transition

The biggest lever is muscle preservation. ≥1.6 g/kg protein distributed across 3–4 meals daily, ≥3 g leucine per meal (Mozaffarian 2025 AJCN). Resistance training 3–5 sessions per week — compound lifts (squat, deadlift, press, row, pull-up), progressive overload from week 1 of the taper, not after. The active LEAN Mass RCT (NCT06885736) is testing resistance-training interventions specifically during GLP-1 discontinuation; no results yet.

Pharmacological adjuncts cover specific gaps that retatrutide was filling — they aren't proven replacements:

• Tesamorelin if waist, VAT, or liver markers drift. Pulsatile GH release reduces visceral adipose and liver fat (Stanley 2019 Lancet HIV); doesn't reproduce the GLP-1/GIP/glucagon triple-agonist effect. See Retatrutide Dual-Axis.
• MOTS-c if training output, fatigue, or insulin sensitivity worsen. Mitochondrial-derived peptide; activates AMPK (Lee 2015 Cell Metab). Post-retatrutide human protocol evidence is thin. See MOTS-c.
• NAD+ if fatigue or low intake fits. Cofactor layer for fat oxidation; demand rises as glucagon-driven oxidation fades. See Retatrutide + NAD+ Protocol.

If using an adjunct, start during Phase 1 of the taper rather than waiting until weight is moving the wrong direction.

When to restart vs stay off

Decision framework, not a prescription. Restart decisions belong with a clinician.

Red flags — evaluate low-dose restart:

• >5% weight regain over 8 weeks despite protocol adherence
• Visceral fat markers rebounding despite tesamorelin
• HbA1c drift above pre-drug baseline
• Strength declining month-over-month despite protein and session consistency

Green flags — stay off:

• Weight stable ±3 lb over 12 weeks
• Strength trending up
• Glucose and lipid panels stable or improving
• Subjective energy and food-noise levels manageable

If restart is indicated, lower-dose re-entry is usually more rational than returning to peak dose. The set-point biology behind Sumithran 2011 is a 12-month story; some people need longer pharmacological assistance than a single cycle.

What's not yet known

Retatrutide is investigational. Phase 3 is reading out through 2026–2027.

• No DXA fat:lean data for non-diabetic obesity yet. TRIUMPH-4 manuscript pending. Tirzepatide's measured 75:25 fat-to-lean preservation ratio doesn't necessarily transfer.
• No published step-down maintenance protocol. The 12 → 8 → 4 mg rhythm above is mechanism-derived, not measured.
• No head-to-head vs tirzepatide. TRIUMPH-5 (NCT06662383) will produce the first direct dose-matched comparison.
• No retatrutide-specific population PK by body weight. The lean-user math uses class analogy from semaglutide and tirzepatide PK literature, not direct retatrutide measurement.
• Long-term safety beyond Phase 2 (12 mg × 48 wk) is not yet characterized. TRIUMPH-Outcomes (n=10,000 cardiovascular and renal endpoints) is the chronic-duration trial.

The microdose case is the strongest evidence position in the GLP-1 class — the 1 mg arm of Phase 2 produced direct measurement. The high-dose long-term safety case carries materially more uncertainty than tirzepatide or semaglutide do at comparable durations.

FAQ

Related Topics

• Retatrutide Deep Dive — full mechanism, trial cohorts, body-composition data
• Retatrutide vs. Tirzepatide — direct comparison
• Retatrutide Dual-Axis Protocol — advanced stacking for recomposition
• Retatrutide + NAD+ Protocol — cofactor layer during active dosing
• GLP-1 Hub — broader GLP-1 family coverage
• GLP-1 Dosing Optimizer — interactive frequency calculator with plasma curves
• Full Reconstitution Calculator — all peptides, cocktails, custom BAC volumes
• GLP-1 Muscle Preservation — protect muscle during weight loss

Appendix: Receptor Math

Full EC50 readings (Coskun 2022 Table S1)

Retatrutide is a full agonist at all three receptors at cAMP signaling — E_max equals or slightly exceeds native peptide peak. Earlier framings as "0.34× partial / 0.4× softened agonism" mistook potency ratio (EC50_LY ÷ EC50_native) for efficacy multiplier (E_max_LY ÷ E_max_native) and have been retracted by Coskun's group. The numbers in the main-body comparison table reflect potency, not efficacy.

β-arrestin biased agonism at GLP-1R. Reta E_max at the β-arrestin recruitment pathway = 40% of native, vs semaglutide 106% (full) and tirzepatide partial in the same direction. Class positioning: biased agonist (cAMP-preserving, β-arrestin-reduced). Qualitative kinetic context for tachyphylaxis and tolerability discussions; not a quantitative prediction in this corpus.

Receptor occupancy at clinical doses

Total-drug receptor occupancy with HSA-scaled EC50s at physiological albumin (4.5%):

pRO = Cav,ss / (Cav,ss + EC50_4.5%_HSA)

EC50s used: GIPR 19.6 nM, GLP-1R 309 nM, GCGR 7,425 nM. These are Coskun 2022 Table S2 values measured at 1% HSA (4.36 / 68.6 / 1,650 nM) scaled linearly by 4.5× to physiological albumin. The ±15% bracket reflects the linear-scaling assumption — defensible because the drug-to-albumin ratio at the highest clinical exposure (12 mg Cav,ss = 342 nM total drug, albumin ≈ 600 μM) is 5.7×10⁻⁴, three orders of magnitude below stoichiometric saturation of albumin's fatty-acid binding sites.

GIPR saturates fast (57% by 1 mg, near-ceiling at 4 mg). GLP-1R climbs steadily to roughly half-engaged at 12 mg. GCGR engagement is supra-fasting-endogenous at every dose but always sub-meal-peak in absolute terms — that's why the glucagon-arm tissue effects activate at thresholds rather than continuously. The bracket roughly doubles around the central GCGR pRO; downstream claims that hang on GCGR engagement (hepatic fat reduction, ANGPTL3/8, REE elevation, peak heart rate) carry that doubled uncertainty.

Earlier versions of this article used a free-drug Cav,ss × no-HSA EC50 method with a t1/2-derived free-fraction estimate. The total-Cav,ss × HSA-scaled EC50 approach above is methodologically tighter — it uses Coskun's directly measured 1% HSA values rather than back-calculating free fraction from half-life — and lands at slightly higher GIPR pRO at low doses (40% vs 31% at 0.5 mg, 57% vs 47% at 1 mg). The narrative claim still holds: 1 mg of retatrutide reaches more GIP engagement than tirzepatide does at its 15 mg ceiling (tirz 15 mg GIPR pRO ≈ 55% with the same scaling method).

References

¹ Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023: 10.1056/NEJMoa2301972 — Phase 2 dose-response (1, 4, 8, 12 mg arms, 48 wk, non-diabetic obesity); per-arm-per-initial-dose split tables; HR Δ at 24 wk; AE temporal pattern (Figure S9); responder distributions.

² Hyperbolic saturation — receptor occupancy = [free drug] / ([free drug] + EC50). Standard Hill-equation pharmacology applied to retatrutide's free-drug Cav,ss and Coskun 2022 binding constants. The first 1 mg crosses the steepest portion of the GIP curve; subsequent dose increases produce diminishing returns. Retatrutide's GIP receptor binding constant is ~16× lower (tighter) than tirzepatide's, which is why the GIP curve fills faster on retatrutide than the equivalent dose of tirzepatide would.

³ Tissue-threshold split — receptor density, downstream signal amplification, and per-tissue glucagon sensitivity differ across liver, visceral fat, sinus node, and subcutaneous fat. Thresholds derived from Phase 2 dose-response data and tissue-specific glucagon receptor pharmacology.

⁴ Downstream saturation / spare receptor — full physiological response often achieved at 10–20% receptor occupancy because the cell's downstream signaling pathway has its own ceiling. Standard receptor pharmacology principle, applied to incretin signaling.

⁵ White-fat futile calcium cycling — chronic GIPR engagement on white adipocytes triggers SERCA-mediated ER calcium leak; the pump runs continuously, burning ATP and forcing the cell to oxidize stored fat for fuel. Yu 2025 Cell Metabolism.

⁶ Sanyal AJ, et al. Retatrutide MASLD substudy. Nature Medicine 2024: s41591-024-03018-2 — 48-week MRI-PDFF liver fat reduction (51% at 1 mg, 86% at 12 mg); VAT and ASAT data; insulin and lipid panels; β-hydroxybutyrate as biomarker of hepatic fatty-acid oxidation.

⁷ Cardiac BMR cost — each ~1 bpm of sustained resting HR adds 30–50 kcal/day from cardiac muscle work. Use raw HR Δ for this calculation, not placebo-subtracted (placebo arm shows real cardiovascular adaptation from weight loss + lifestyle counseling, so subtraction over-corrects for drug-attributable cost).

⁸ Eli Lilly press release, December 11, 2025 — TRIUMPH-4 Phase 3 results in obesity + osteoarthritis; 12 mg = 28.7% weight loss at 68 weeks. investor.lilly.com.

⁹ Population PK exposure shift by body weight — derived from class-analogous semaglutide and tirzepatide population-PK literature (Carlsson Petri 2018 Diabetes Therapy; Schneck 2024 CPT). Retatrutide-specific body-weight covariate not yet published; class analogy applied. A 70 kg user lands at approximately 1.4–1.6× the exposure of an 85 kg reference subject at the same nominal dose.

¹⁰ Within-pair titration analysis — Jastreboff 2023 supplementary tables S4 + S5, Figure 1A trajectory data, Figure S9 panel A AE temporal data. Slow vs fast titration compared at matched final maintenance dose for both 4 mg and 8 mg cohorts; waist-circumference-to-weight-loss ratios at week 4 used as quasi-DEXA proxy for fat-vs-lean distribution.

¹¹ Adaptation pathways (brainstem nausea circuit, sinus-node baroreflex) respond to rate of change in receptor occupancy; efficacy pathways respond to cumulative exposure over time. This is why slow titration produces fewer side effects at the same final dose.

¹² Coskun T, et al. Retatrutide discovery and receptor pharmacology. Cell Metabolism 2022: 10.1016/j.cmet.2022.07.002 — receptor binding constants (GIP EC50 0.0643 nM, GLP-1 0.775 nM, glucagon 5.79 nM); potency ratios vs native peptide (GIP 8.9× more potent than native, GLP-1 2.5× less potent, glucagon 2.9× less potent); full agonist at all three at cAMP signaling (E_max numbers in ref ¹⁵); ~6-day half-life; structural design. Earlier framings of these numbers as "intrinsic efficacy multipliers" or "partial agonist" were a measurement-mislabel and are retracted.

¹³ T3 suppression on GLP-1 / GIP / glucagon agonism — caloric deficit and hepatic energy expenditure together downregulate T4-to-T3 conversion; Free T3 drops while TSH stays in range. See GLP-1 fatigue guide for monitoring.

¹⁴ Cross-class GIPR engagement comparison — retatrutide GIPR EC50 0.0643 nM (Coskun 2022) vs tirzepatide GIPR EC50 ~1.01 nM (Willard FS, et al. JCI Insight 2020;5(17): 10.1172/jci.insight.140532). Retatrutide's binding constant is ~16× tighter — meaning meaningful engagement happens at a fraction of tirzepatide's dose. At 1 mg, retatrutide engages 47% of GIP receptors; tirzepatide reaches ~41% only at 15 mg. Both compounds are full agonists at GIPR cAMP signaling; once engaged, each receptor fires at native-equivalent peak strength.

¹⁵ Coskun 2022 mmc1 Table S1 + Table S2 — receptor functional activity at cAMP signaling. Retatrutide E_max at GIPR 103%, GLP-1R 110%, GCGR 104% of native peptide peak (full agonist at all three at cAMP signaling per the conclusions section: "LY3437943 is a full agonist at the GCGR, GIPR, and GLP-1R in the functional assays"). At a separate β-arrestin recruitment pathway at GLP-1R, reta E_max = 40% of native (partial / biased agonism), tirzepatide partial in the same direction, semaglutide full at both pathways. Earlier framings of "0.34× partial agonist at GCGR" or "0.4× softened agonist at GLP-1R" mistook potency ratios (EC50_LY ÷ EC50_native) for efficacy multipliers (E_max_LY ÷ E_max_native) and are retracted.

¹⁶ Coskun 2022 mmc3 Table 3 + mmc1 Table S8 — Phase 1 single-ascending-dose study (NCT03841630, n=45, conducted in Singapore). Population: 97.8% Asian, 93% male, mean weight 76.7 kg, mean BMI 26.3, healthy non-diabetic. Per-cohort baseline weight + BMI: 0.3 mg cohort 67.5 kg / BMI 23.2; 1 mg cohort 73.5 kg / BMI 26.1; 4.5 mg cohort 69.9 kg / BMI 23.2 (the leanest cohorts). Pulse rate 8-day average LSM CFB: placebo +5.0; 0.1 mg +2.4; 0.3 mg +7.6; 1 mg +10.3; 3 mg +16.7; 4.5 mg +25.2; 6 mg +19.3 (3 mg and above statistically significant vs placebo). Day 4–6 peak (Figure S4C) approximately 1.5–2× higher than the 8-day average. Returns toward baseline by day 29–43.

¹⁷ Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol 2024;13:494–503: 10.1002/psp4.13099. 39,644 samples, 5,802 participants, 19 studies. Two-compartment model with first-order absorption + elimination; F = 0.8 fixed; ka = 0.0373 /h; TVCL = 0.0329 L/h/70 kg; allometric exponent on CL = 0.8 (BW^0.8); allometric exponent on Vd = 1.0 with FFM + 0.482·FM scaling; mean t½ = 5.4 days; accumulation R at QW = 1.7×. Used as donor PopPK structure for the retatrutide PK bridge — the BW^0.8 allometric exponent is internally validated against retatrutide in Rosenstock 2023 arm pairs (4 mg ID2 at 108.3 kg vs 4 mg ID4 at 93.1 kg: predicted Cav,ss ratio 1.13, observed 1.18, 4.8% error), so the borrowing is tirz-prior, reta-confirmed rather than tirz-substituted.

Appendix: How these numbers were built

The lean-user weight-loss projections, the heart-rate-as-cardiac-cost numbers, the HSA-scaled receptor occupancies, and the Cmax-versus-Cavg framing all rest on a specific reconstruction architecture. This appendix walks through it for readers who want to verify a number or extend the math to a phenotype the article doesn't cover.

The architecture, in one paragraph

Retatrutide direct cohort data anchors every (dose × phenotype × time × axis) point we have measured: Jastreboff 2023 Phase 2 obesity at 109 kg / BMI 37 / 48 wk; Sanyal 2024 MASLD substudy at the same cohort with elevated baseline liver fat; Coskun 2022 Phase 1 SAD at 76.7 kg / BMI 26.3 / single dose, day-43 follow-up. Where reta lacks data — chronic dosing in lean recomp users, BMI strata other than the Jastreboff mean, time points beyond Coskun's 43-day window — tirzepatide cohort data (Schneck 2024 PopPK + SURMOUNT-1 BMI strata at 10/15 mg / 72 wk) provides math structure: slopes, ratios, and curve shapes. The tirz cohort response is not substituted for reta response. It supplies the parametric extrapolation tools that fill reta gaps.

Anchor cohorts and the PK bridge

The PK bridge formula:

Cav,ss(user) = Cav,ss(anchor) × (BW_anchor / BW_user)^0.8

The 0.8 exponent comes from Schneck 2024 tirz PopPK (semimechanistic allometry) and is internally validated against retatrutide using Rosenstock 2023 arm pairs at the same nominal dose with different cohort body weights — predicted vs observed Cav,ss ratios match within 5%. For BMI 22–38 the simplified formula matches the full Schneck model (which separates fat-free mass and fat mass with a 0.482 fat-fraction coefficient on volume of distribution) within ~5%. Above BMI 38 or below BMI 22, the body-composition split matters more and the full FFM/FM-stratified model should be used.

HSA-scaled receptor EC50s

Coskun 2022 Table S2 measured EC50s in cAMP assays with 1% human serum albumin added. Physiological serum has ~4.5% albumin. The L2 scaling convention is linear: multiply the 1% HSA EC50 by 4.5 to estimate the apparent EC50 at physiological albumin.

The linear scaling assumption holds at clinical concentrations because the drug-to-albumin ratio at the highest clinical exposure (12 mg Cav,ss = 342 nM total drug; albumin ≈ 600 μM) is 5.7×10⁻⁴ — three orders of magnitude below stoichiometric saturation of albumin's fatty-acid binding sites. Native-ligand controls (glucagon, GIP, GLP-1) shift only 1.07–1.21× at 1% HSA, bounding the assay-buffer-chemistry contribution; the bulk of the apparent EC50 shift is the binding effect, which extrapolates linearly.

The ±15% bracket is the operating uncertainty on physiological-serum EC50, propagated to all downstream pRO calculations. The case for inheriting tirzepatide albumin-binding behavior into reta — both compounds use identical C20 fatty diacid + γGlu-AEEA spacer chemistry, differing only in peptide-anchor position (Lys17 in reta, Lys20 in tirz; Li 2024 cryo-EM at 2.68 Å resolution confirms the shared linker design), and reta Vz/F is indistinguishable from tirz Vc + Vp at the PopPK level — narrows the bracket from earlier ±30% versions.

Tirzepatide BMI gradient as extrapolation parameter

Tirz cohort data is used as math structure (slope, ratio, curve shape), not as cascade-response baseline. The relevant gradient comes from SURMOUNT-1 non-T2D obese at 15 mg / 72 wk, BMI-stratified placebo-adjusted weight loss:

Slope between BMI 27.5 and 37.5: about −0.6 percentage points of weight loss per BMI unit. Plateau above BMI 37.5 (the response asymptotes; further BMI increases don't buy more weight loss).

This gradient is used in two ways:

• BMI ratio: tirz response at target BMI ÷ tirz response at anchor BMI = the proportional adjustment factor for reta.
• BMI absolute slope: tirz Δ across the BMI step = the absolute pp adjustment for reta.

Both methods get applied to the reta anchor; the bracket between them is part of the projection's uncertainty.

Time-course shape from SURMOUNT-1

Tirz weight-loss trajectory shape lets us extend reta data across follow-up timepoints (Jastreboff is 48 weeks; chronic projections often need 24, 36, or 72 weeks):

The shape is class-typical for long-acting incretin agonists; reta's own Jastreboff trajectory (week 24 ≈ −17.5%, week 48 = −24.2%) gives a 72% wk-24/wk-48 ratio that's consistent with this curve.

Worked example: BMI <30 lean user at 12 mg / 48 weeks

Anchor: Jastreboff 12 mg / 48 wk at BMI 37 = −24.2% body weight.

Method A (BMI ratio):

• Tirz BMI 27.5 ÷ BMI 37.5 = −13.1 ÷ −19.3 = 0.679
• Apply to reta anchor: 0.679 × −24.2% = −16.4%

Method B (BMI absolute slope):

• Tirz Δ across BMI 27.5 → 37.5 = −19.3 − (−13.1) = −6.2 pp
• Apply to reta anchor: −24.2 − (−6.2) = −18.0%

Bracket: reta 12 mg / 48 wk at BMI 27.5 ≈ −15 to −19%, with about ±2 pp from method choice and ±2 pp from cohort-variance inheritance.

For higher-BMI users (≥40), the tirz plateau suggests reta also plateaus at or near its BMI-37 anchor — reta 12 mg / 48 wk at BMI ≥40 ≈ −23 to −25%, essentially unchanged from the Jastreboff reading.

Worked example: lean recomp at 1 mg chronic / 48 weeks

Anchor: Coskun 1 mg single dose in BMI 26 healthy = ~−1 kg / 43 d ≈ −1.4% body weight (Figure 4C estimate from the 76.7 kg cohort mean).

Two scaling steps:

1. Single dose to chronic steady state. Schneck-derived accumulation factor at QW dosing is 1.7–1.8× on Cmax. But weight loss is sub-linear with exposure (Hill saturation above receptor saturation), so the response amplification is larger than 1.8× when measured across multi-week cumulative dosing.
2. Time extension. Tirz SURMOUNT-1 BMI <30 stratum reaches −13.1% at 15 mg / 72 wk. The single-dose-equivalent (acute response in the equivalent cohort) is much smaller. The implied scaling factor from acute single-dose to 72-week chronic SS is roughly 6–10× amplification at matched receptor engagement — which is what the time-course curve buys when the drug accumulates and the response builds.

Apply to reta single-dose anchor:

• 1 mg single-dose: −1.4% acute (Coskun)
• × 6–10 amplification: −8 to −14% / 72 wk chronic SS
• Time-correct to 48 weeks (×0.92): −7 to −13% / 48 wk
• Time-correct to 24 weeks (×0.75): −6 to −10% / 24 wk

The bracket is wide because reta has no chronic data at this phenotype, tirz lacks a true lean-cohort validation (SURMOUNT-1 enrolled BMI ≥27), and Coskun is 98% Asian and 93% male — any cross-ethnic or cross-sex translation adds variance. The directional claim (meaningful weight loss happens at sub-trial-cohort doses for lean users) is robust; the magnitude is the part with the wide band.

Cmax / Cavg at chronic steady state

For weekly SC dosing with ~6-day half-life and ka fitted to Coskun's Tmax data (12–72 h depending on dose, ka ≈ 0.05 /h):

The Cmax-driver tolerability framing (peak concentration triggering nausea and autonomic spikes) lands hardest in three specific scenarios:

• First dose — Cmax is only 52% of the eventual SS Cmax, but the user has zero prior receptor adaptation, so the absolute exposure jump is the load.
• Each titration step — the new dose adds a Cmax bump above the prior steady state that decays into the new steady state over ~3–4 weeks (the adaptation-debt window the article describes).
• Missed-then-redose — Schneck simulated this for tirz: a 4-day-late redose produces a transient ~20% Cmax spike on the next regular injection.

At chronic maintenance on a held dose (≥4 weeks), Cmax oscillates only ~22% above Cavg. The peak-vs-average differential is muted; tolerability scales with average exposure rather than peak oscillation.

What these projections are and aren't

The bracketed ranges in this article are directional inference anchored to specific cohorts, not point predictions. The bands are wide because metabolic state is multidimensional and individual variance within any cohort is large — two users with identical BMI, age, and resting heart rate will sit at different points on the response curve because the latent dimensions (heart-rate variability, autonomic reactivity, training status, sleep, mitochondrial function, hormonal axes) shift their cascade response amplitude in ways the conventional markers don't capture.

The reta direct anchors are the load-bearing data. Tirz cohort data fills extrapolation gaps via slopes and curve shapes — it does not substitute tirz response for reta response at any phenotype. Cross-compound observations between reta and tirz cohorts at roughly matched dose × phenotype × time are empirical observations, not subtraction-derived mechanism claims; the GCGR-attributable interpretation of those observations is a defensible reading but not load-bearing on the projection framework.

The reta receptor pharmacology, the reta single-dose PK and PD, and the reta chronic cohort weight-loss data are fixed primary-source measurements. The tirz extrapolation parameters are fixed primary-source measurements. The math that connects them — and that lands a 75 kg BMI 26 user somewhere in a −7 to −13% / 48 wk bracket at 1 mg weekly — is constructive inference, defensible at the directional level and bracketed at the magnitude level.